Previous Close | 15.20 |
Open | 38.00 |
Bid | 15.10 x 0 |
Ask | 15.60 x 0 |
Day's Range | 15.00 - 15.80 |
52 Week Range | 10.80 - 42.80 |
Volume | |
Avg. Volume | 179 |
Market Cap | 726.438M |
Beta (5Y Monthly) | 2.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.45 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 44.25 |
NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor ...
Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 [1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis ...
With the business potentially at an important milestone, we thought we'd take a closer look at Protagonist...